HistoSonics

19 articles about HistoSonics

• HistoSonics Awarded Key Position in UK’s Novel Innovation Program

  2/14/2024

  HistoSonics® announced that the company’s Edison System has been selected to participate in the UK’s newly created Innovative Devices Access Pathway Pilot Program designed to accelerate the development of cost-effective medical devices and their integration into the UK market.

• World’s First Kidney Tumor Treated Using the HistoSonics’ Edison® Histotripsy System

  1/9/2024

  HistoSonics, Inc., (www.histosonics.com), developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the treatment of the first patient in its pivotal #HOPE4KIDNEY Trial.

• HistoSonics Notches Significant Reimbursement Wins

  11/6/2023

  HistoSonics, the manufacturer of the non-invasive Edison® Histotripsy System and novel sonic beam therapy, announced that the Centers of Medicare & Medicaid Services set a new payment rate for histotripsy of liver tumors procedures, increasing the payment rate to $17,500.

• HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy

  3/30/2023

  HistoSonics, the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced the first kidney patient has been treated using the Company's histotripsy platform.

• HistoSonics Announces Published Results of Phase I Liver Tumor Trial

  9/19/2022

  HistoSonics announced today the publication of results from their prospective Phase I clinical trial, named the THERESA Trial, conducted in Barcelona, Spain.

• HistoSonics Announces Milestone As American Medical Association Issues Unique Category III CPT® Code For Histotripsy Of Liver

  7/12/2021

  HistoSonics, is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver.

• HistoSonics Announces First Patient Treated in European Clinical Trial

  6/7/2021

  Otto von Guericke University Clinic Magdeburg is first to treat patient with liver tumors in company's #HOPE4LIVER Europe Study

• HistoSonics Receives Approval To Begin European #HOPE4LIVER Clinical Study

  1/11/2021

  HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval to initiate the company's second European clinical trial of its new platform technology

• HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study

  10/5/2020

  HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to b

• HistoSonics Announces $40 Million Financing

  6/8/2020

   HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an oversubscribed Series C-1 financing.  The round was led by Yonj

• /C O R R E C T I O N -- HistoSonics, Inc./

  6/12/2019

  HistoSonics, Inc., developer of a non-invasive robotics platform and novel sonic beam therapy, announced that promising new clinical and preclinical data were presented at the 2019 Society of Interventional Oncology (SIO) Annual Meeting in Boston, Massachusetts.

• HistoSonics, Non-Invasive Robotics Pioneer, Releases Promising Data at Society of Interventional Oncology (SIO)

  6/11/2019

  Four abstracts presented including first-in-human results in liver tumors and preclinical evidence of histotripsy-induced immune response using novel sonic beam therapy

• HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing

  4/8/2019

  Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy

• HistoSonics Selected as One of the Hottest Startups at the 2019 J.P. Morgan Healthcare Investment Conference

  1/7/2019

  Non-Invasive Surgical Robotics Company with "Pure Sci-Fi" Technology Joins The Observer's List of Top Firms

• HistoSonics Expands Leadership Team As It Accelerates Growth

  9/20/2017

• HistoSonics Appoints Mike Blue As CEO And Board Member; Completes First Close Of A Series B Financing

  3/13/2017

• Tumor Ablation Expert Dr. Fred Lee, Jr. Joins HistoSonics As Board Member, Senior Medical Advisor

  9/16/2016

• HistoSonics Close To Bagging $14.2 Million For Non-Invasive Ablation

  5/21/2014

• HistoSonics Raises $11 Million

  1/5/2010